Retifanlimab for Colorectal Cancer

"At this juncture, the trial is not currently enrolling participants; it was first submitted to clinicaltrials.gov on January 1st 2023 and last updated August 5th 2022. If you are in search of other studies, there are presently 3641 ongoing trials with metastatic colorectal cancer (crc) patients, as well as 26 Recifanlimab related investigations looking for enrollees."

"As this is primarily a Phase 1 trial, meaning there has been limited data to evaluate the safety and efficacy of Retifanlimab, we at Power rate it as a 1."

"Currently, there are 26 trails investigating the efficacy of Retifanlimab with 3 in Phase 3. Among them are two in A CORU�A and Virginia respectively; however 810 sites across the globe have launched studies into Retifanlimab's medicinal applications."

"Research into Retifanlimab began in 2016, when Incyte Corporation sponsored a clinical trial with 325 participants. This led to the drug's Phase 1 approval and presently there are 26 active trials for it across 117 cities and 43 countries."

"At the moment, this medical investigation is unable to accept patients. It was first advertised on January 1st 2023 and last updated on August 5th 2022. For those eager to join a study, there are currently 3641 trials recruiting for metastatic colorectal cancer (crc) and 26 studies welcoming participants with Retifanlimab."

"According to Incyte Corporation, the primary endpoint of this trial will be measured over a two year period and is Percentage of patients who receive at least one dose of personalized neoantigen vaccine. Assessing other outcomes such as Overall Survival (OS), Objective Response Rate (ORR) per RECIST 1.1, and Progression-free Survival (PFS) per RECIST 1.1 are also part of the secondary objectives in which OS is defined as the number of months from date of first personalized vaccine dose until death or end of follow-up; ORR is determined by the number achieving CR or PR based on Response Evaluation"